Concept Life Sciences Expands Integrated Drug Discovery Facilities




Concept Life Sciences Expands Integrated Drug Discovery Facilities

Establishes one of the UK’s largest drug discovery research sites

Site officially opened by local MP Jonathan Pearce

CHAPEL-EN-LE-FRITH, United Kingdom, Sept. 26, 2025 (GLOBE NEWSWIRE) — Concept Life Sciences, a leading contract research organisation (CRO) serving the global life sciences and pharma industry, today announces the official opening, by Jonathan Pearce, the Labour Member of Parliament for High Peak, of its expanded integrated drug discovery facilities at its Chapel-en-le-Frith site. This expansion brings chemistry, ADMET and screening biology capabilities together under one roof with 130 scientists now on site.

This represents a key milestone in the Company’s mission to accelerate the development of life-changing therapies, enhancing its ability to provide streamlined integrated drug discovery services that unlock progress in early-stage innovation through efficient workflows and troubleshooting.

Jon Pearce, MP, High Peak, said: “It is fantastic to see Concept Life Sciences investing in Chapel-en-le-Frith and creating one of the UK’s leading drug discovery research sites here in High Peak. This expansion not only brings high-skilled, high-value jobs to our community, but also puts our region at the forefront of groundbreaking work to develop life-changing therapies. It shows the enormous potential for growth in life sciences both here in High Peak and across the UK, building on our proud tradition of innovation while helping to secure the high-quality jobs of the future. By investing in world-class science locally, we are supporting both our local economy and the UK’s global leadership in the sector.”

The expanded state-of-the-art facilities, which include custom-fit drug discovery solutions across a broad range of modalities and therapy areas, are also expected to provide high-value life-sciences job opportunities in the Manchester and Sheffield region. The Company’s headquarters is now one of the UK’s largest drug discovery research sites.

Jonathan Critchley, Chief Financial Officer at Concept Life Sciences, commented: “This expansion of our facilities further strengthens our ability to turn breakthrough science into viable, fundable and clinically impactful therapies through our integrated drug discovery capabilities. As an agile, client-centric CRO, with world-leading scientific and regulatory expertise, we don’t just deliver on the science for our clients, we provide a tailored solution-oriented approach to enable early-stage research companies to overcome unique drug discovery challenges.”

About Concept Life Sciences

Concept Life Sciences is a leading contract research organisation (CRO) serving the global life sciences industry. For over 25 years, CLS, and its heritage companies, have provided consultative, and collaborative, drug discovery and development services. Our approach, supported by passionate scientists and world-leading capabilities, enables us to overcome complex scientific challenges across a broad range of therapeutic areas, improving success rates for translating innovations into viable therapeutics. To date, Concept Life Sciences has successfully helped 29 candidates advance to the clinic.

The company offers sophisticated translational biology services coupled with exceptional end-to-end chemistry capabilities offering concept to clinic solutions. Across modalities, including small molecules, biologics, peptides, and cell & gene therapies, Concept Life Sciences seamlessly integrates capabilities and provides bespoke solutions to address drug discovery challenges.

Collectively, the company’s high-quality services across the drug discovery and development pathway have helped its customers advance their drugs from concept to clinic in as little as 32 months, well ahead of the industry average of 60 months.

Driven by a passion for science, Concept Life Sciences has around 230 employees, with over 70% holding PhDs. The company operates from state-of-the-art UK facilities, headquartered near Manchester, with additional specialist operations in Edinburgh, Dundee, and Sandwich.

Visit us at www.conceptlifesciences.com and follow us on LinkedIn.

Media contacts

Concept Life Sciences
Clare Whitewoods – Marketing Director
Clare.Whitewoods@conceptlifesciences.com

Scius Communications
Katja Stout
+44 778 943 5990
katja@sciuscommunications.com 
Daniel Gooch
+44 7747 875479
daniel@sciuscommunications.com 

Fangzhou’s ‘XingShi’ LLM Featured by Nature News and Xinhua, Showcasing AI Innovation in Chronic Disease Care




Fangzhou’s ‘XingShi’ LLM Featured by Nature News and Xinhua, Showcasing AI Innovation in Chronic Disease Care

SHANGHAI, Sept. 26, 2025 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), a leader in AI-driven Internet healthcare solutions, announced that its “XingShi” Large Language Model (“XS LLM”) was featured by Nature News under the headline “A Chinese AI tool can manage chronic disease — could it revolutionize health care?”

The article, written by science reporter Mohana Basu, cited the model’s potential applications for chronic disease management, while citing expert commentary. Xinhua News Agency also highlighted the piece under the headline “Nature focuses on Fangzhou’s XS LLM: Chinese AI tackling global chronic disease challenges.”

This recognition underscores the growing role of AI in addressing global health issues. Fangzhou’s XS LLM, released in September, was designed to address ongoing healthcare challenges such as low chronic disease management efficiency, while enabling greater customization of services, and more effective use of physicians’ constrained schedules.

“Recognition from Nature demonstrates that Chinese innovation in AI-driven healthcare is earning global attention,” said Fangzhou’s Founder, Chairman and CEO Dr. Xie Fangmin. “With the XS LLM, we aim to provide a scalable, reliable and patient-centered solution that can not only transform chronic disease management in China but also offer insights for healthcare worldwide.”

XS LLM integrates multimodal capabilities — image and speech recognition, natural language processing, large-scale medical knowledge storage, and reasoning — while achieving advanced performance benchmarks in medical AI. This core system supports five domain-specific intelligent agents: “AI Knowledge Agent”, “AI Guidance Agent”, “AI Pre-Consult Agent”, “AI Doctor Assistant”, and “AI-Electronic Medical Record (EMR) Agent”. Together, these agents create a closed-loop service architecture spanning the full lifecycle of chronic disease management.

Built as the “core digital brain” of Fangzhou’s platform, the model currently powers five AI-enabled applications: AI Medication Finder, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI-Powered Search. Each product addresses distinct clinical and patient-side use cases, enabling real-time, precision interventions across medication guidance, patient education, diagnostic assistance, and medical reference.

Nature news feature spotlighted Fangzhou’s XS LLM as a pioneering tool for chronic disease care, highlighting its integration of image, speech and language capabilities along with medical reasoning to improve personalized care — reporting that the platform already supports over 50 million registered users and over 200,000 physicians — and positioning it as a major example of China’s AI innovation entering the global healthcare stage.

Fangzhou has also proactively addressed risks of “AI hallucination” through data tuning refinements, model optimization, enhanced supervision and regulatory compliance upgrades. The Company has said that it will continue to deepen its AI research and expand applications across chronic disease care, further contributing to the “Healthy China 2030” initiative.

About Fangzhou Inc.
Fangzhou Inc. (06086.HK) is China’s leading online chronic disease management platform, serving 52.8 million registered users and 229,000 physicians (as of June 30, 2025). The Company specializes in delivering tailored medical care and AI-enabled precision medicine solutions. For more information, visit https://investors.jianke.com.

Media Contact
For further inquiries or interviews, please reach out to:
Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com

Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements

Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs




Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reiterated that its allogeneic cell therapy products are manufactured from U.S. donors in the U.S. and designated as U.S. origin products not subject to tariffs on imported branded or patented pharmaceutical products.

Ryoncil^® (remestemcel-L) is the only allogeneic mesenchymal stromal cell therapy approved by U.S. Food and Drug Administration (FDA) for any indication. As documented in the Company’s Biologic License Application (BLA), Ryoncil^® is designated a ‘U.S. Country of Origin’ product in line with U.S. FDA and Customs regulatory guidance.

Ryoncil^® is approved for treatment of pediatric patients 2 months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease (SR-aGvHD), a condition with high mortality rates.

Mesoblast continues to ensure that all its products, whether for SR-aGvHD, chronic heart failure, chronic back pain, or other inflammatory indications, are manufactured from U.S. donors at U.S. sites.

About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast’s Ryoncil^® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.

Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil^® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.

About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercial protection extending through to at least 2041 in major markets.

About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s Ryoncil^® for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025




Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025

Geneva, Switzerland, September 26, 2025 – Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Half-Year and Second Quarter 2025 Financial Results on September 30, 2025 and host a conference call to discuss the results on October 1, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on October 1, 2025.

Title:   Addex Therapeutics Reports Half-Year 2025 Financial Results and Provides Corporate Update
Date: October 1, 2025
Time: 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) 

Joining the Conference Call:

1. Participants are required to register in advance of the conference using the link provided below. Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique Personal PIN.
2. In the 10 minutes prior to the call’s start time, participants will need to use the conference access information provided in the e-mail received at the point of registering. Participants may also use the call me feature instead of dialing the nearest dial in number.

Webcast registration URL:

https://edge.media-server.com/mmc/p/vh6nhzwt

Conference call registration URL:

https://register-conf.media-server.com/register/BI403a5726888046a6a0645698cc9fdaec

About Addex Therapeutics

Addex is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex’s partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit www.addextherapeutics.com
  
Contacts: 

Addex Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy




OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy

OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy

NANTES, France – September 26, 2025, 7:00 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), Inserm Transfert (on behalf of Inserm, a French public organization dedicated to human health), and Nantes University today announce the signing of a strategic partnership agreement aimed at accelerating the development of innovative projects in the fields of immunotherapy for oncology, inflammation, and autoimmunity.

By combining academic research with industrial expertise, the partnership seeks to transform cutting-edge immunology discoveries into industrial programs capable of delivering breakthrough therapies to patients. This large-scale public–private alliance strengthens long-standing ties with the Immunotherapy Innovation Hub in Nantes and sets the stage for expanding this collaborative model nationwide in the years ahead.

To achieve these objectives, the partners will unite their scientific teams and pool their expertise and know-how to transform innovative projects into programs ready for industrial development. As part of this new partnership, the project identification process led by Inserm Transfert and Nantes University will enable OSE Immunotherapeutics to access the most promising and relevant programs emerging from the research units of Nantes University and Inserm. Selected projects will benefit from financial support and dedicated guidance.

Pascale Augé, Chairwoman of the Executive Board of Inserm Transfert, said: “This partnership with OSE Immunotherapeutics perfectly illustrates our commitment to supporting excellence in research by fostering synergies between the academic community and French biotech companies. We are very pleased to strengthen long-term collaborations with innovative players firmly rooted in their region, to the benefit of patients. This is a clear example of the vitality of public–private partnerships in the healthcare sector.”

Frédéric Jacquemin, Vice President for Innovation and Partnerships at Nantes University, adds: “Collaborative research at Nantes University is at the heart of our mission. It is built on our academic and hospital strengths, as well as on strong and recognized partnerships. We look forward to further strengthening the complementarity of our expertise and resources within this partnership, in order to foster open research and drive therapeutic innovation for society.”

Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, comments: “We are very pleased to embark on this new collaboration with outstanding teams whose expertise, technologies, and immunotherapy programs are highly complementary to our own. This partnership strengthens our long-standing ties with academic research in Nantes and extends them nationwide, further supporting our ambition to promote immunological innovation throughout France. It also demonstrates our ongoing commitment to bringing innovative immunotherapies to patients with significant unmet medical needs – a shared and central goal of this alliance.”

ABOUT INSERM TRANSFERT
Inserm Transfert, a private subsidiary of Inserm, is responsible for the development and innovation activities of Inserm and its academic partners in human health and promotes long-term technology transfer in line with international best practices. Founded in 2000, Inserm Transfert manages, under a public service concession, the entire innovation value chain and the transfer of knowledge from Inserm’s research laboratories to industry – from invention disclosure to industrial partnerships and company creation. Inserm Transfert also offers services for the setup and management of national, European, and international projects, as well as support for the development of clinical research and the valorization of health data, databases, and cohorts. To learn more: www.inserm-transfert.fr.

ABOUT NANTES UNIVERSITY
Nantes University is a public institution of higher education and research that offers a unique world-class university model in France, bringing together four academic clusters: Centrale Nantes, the Nantes Saint-Nazaire School of Fine Arts, the Nantes National School of Architecture, the Nantes University Hospital (CHU), the Jules Verne Institute of Technological Research, and Inserm. A major player in research, education, and innovation, Nantes University is particularly renowned for its excellence in health, as demonstrated by the I-SITE (Initiative – Science, Innovation, Territory, Economy) label of excellence awarded through the NExT project, one of whose two thematic pillars is “Health of the Future.” This drive for excellence is based on internationally recognized research and is part of the University Innovation Cluster, led by Nantes University, which supports and promotes collaborative research and technology transfer.

ABOUT OSE IMMUNOTHERAPEUTICS

OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext.

Additional information about OSE Immunotherapeutics assets is available on the Company’s website: www.ose-immuno.com. Follow us on LinkedIn.

Contacts

OSE Immunotherapeutics

Forward-looking statements
This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.

These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.

Attachment

• EN_250926_ACCORD_INSERM_UNIV_NANTES

uniQure Announces Pricing of Upsized $300 Million Public Offering




uniQure Announces Pricing of Upsized $300 Million Public Offering

LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2025 (GLOBE NEWSWIRE) — uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its previously announced underwritten public offering of 5,789,473 ordinary shares at a public offering price of $47.50 per share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase 526,316 of its ordinary shares at the public offering price per share less the $0.0001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, are expected to be approximately $300 million. All securities to be sold in the offering are being sold by uniQure. In addition, uniQure has granted to the underwriters a 30-day option to purchase up to 947,368 additional ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about September 29, 2025, subject to the satisfaction of customary closing conditions.

Leerink Partners, Stifel, Guggenheim Securities and Van Lanschot Kempen are acting as bookrunning managers for the offering. H.C. Wainwright & Co. is acting as lead manager for the offering.

The securities described above are being offered by uniQure pursuant to its automatically effective shelf registration statement on Form S-3 (File No. 333-284168) filed with the U.S. Securities Exchange Commission (the “SEC”) on January 7, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC on September 24, 2025 and a final prospectus supplement and the accompanying prospectus relating to this offering will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at +1 (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8^th Floor, New York, New York 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or Van Lanschot Kempen (USA) Inc., 880 Third Avenue, 17th floor, New York, New York 10022, or by email at equitycapitalmarkets@vanlanschotkempen.com. The final terms of the proposed offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington’s disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases. 

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding our expectations of market conditions, the satisfaction of customary closing conditions and the timing of the public offering, the gross proceeds we expect to receive and other statements identified by words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “shall,” “expect,” “anticipate,” “believe,” “seek,” “target,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict” and similar words or expressions.

Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering, continued interest in our rare disease and gene therapy portfolio, the ability to develop our product candidates and technologies, regulatory developments, the impact of changes in the financial markets and global economic conditions, and other factors described under the heading “Risk Factors” in uniQure’s periodic securities filings with the SEC, including our Annual Report on Form 10-K filed with the SEC on February 27, 2025, our Quarterly Reports on Form 10-Q filed with the SEC on May 9, 2025 and July 29, 2025, the preliminary prospectus supplement filed with the SEC on September 24, 2025 and the accompanying prospectus, and other filings that uniQure makes with the SEC from time to time. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements and, except as required by law, uniQure assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure Contacts

Acıbadem Hospitals Launch “Ready for All Rounds” In‑Hospital Campaign for Breast Cancer Awareness Month




Acıbadem Hospitals Launch “Ready for All Rounds” In‑Hospital Campaign for Breast Cancer Awareness Month

Following last year’s heavy‑bag installation, this year’s activation features pink boxing gloves, a powerful reminder that early detection and multidisciplinary care help patients go the distance.

ISTANBUL, Sept. 25, 2025 (GLOBE NEWSWIRE) — Breast Cancer Awareness Month, observed every October worldwide, is a global health campaign recognised by the World Health Organization and leading cancer societies. Symbolised by the pink ribbon, the month is dedicated to raising awareness, promoting early detection, and supporting those affected by breast cancer through educational events, public screenings, community campaigns and fundraising initiatives.

Acıbadem Hospitals today announced its in‑hospital Breast Cancer Awareness Month campaign, “Ready for All Rounds,” an activation designed to meet patients and visitors where they are inside the hospital with clear calls to action for regular check‑ups and early diagnosis. Building on last year’s heavy punching‑bag installation, this year’s visual focus is pink boxing gloves arranged in the shape of the breast‑cancer ribbon, deployed across clinical corridors, radiology waiting areas, nurse stations, and digital hospital screens. The poster headline “WE ARE READY FOR ALL ROUNDS” with the educational line “Protect yourself with regular check‑ups, and stay strong against breast cancer with early diagnosis” anchors the creative.

“Breast cancer is one of more than 200 tumor types, yet it carries particular weight as the most common cancer worldwide. Each year, around 2.3 million people — predominantly women — receive this diagnosis,” said Professor Metin Çakmakçı, MD, breast‑cancer specialist at Acıbadem. “What changes the story is early detection and a coordinated, expert team.” (Global incidence reference: IARC.)

A campaign built around action inside the hospital

The in‑hospital program ensures that awareness immediately converts into action. Educational posters and screens guide visitors to on‑site breast imaging; staff remind eligible visitors about screening while clinical teams offer same‑day evaluations where appropriate. The creative theme of boxing gloves invites everyone to “step into the ring” for their health while reinforcing a simple message: book the check‑up now.

From first exam to definitive therapy — a comprehensive pathway under one roof

At the Acıbadem Breast Cancer Clinic, patients receive a detailed physical examination followed by appropriate radiologic evaluation (ultrasound, mammography, and/or MRI). When an abnormality such as a lump, mass, or suspicious calcification is detected, a needle biopsy is performed the same day; pathology results are typically ready within 2–3 days to confirm diagnosis and guide treatment. Treatment plans are individualized and may combine surgery, systemic drug therapy (chemotherapy, immunotherapy, targeted therapy, hormone therapy), and radiotherapy using advanced linear accelerators.

“Every physician who touches breast‑cancer care at Acıbadem — from radiology to surgical oncology, medical oncology, radiation oncology, pathology, plastic and reconstructive surgery, and nuclear medicine, literally works on the same corridor,” Prof. Çakmakçı added. “That proximity accelerates decisions, reduces patient anxiety, and improves outcomes, because our team can confer face‑to‑face in minutes rather than days.”

^{Photo: ACIBADEM INTERNATIONAL (from left to right) Prof. Dr. Bülent Saçak, Prof. Dr. Özge Gümüşay, Assoc. Prof. Özden Buturak, Prof. Dr. Metin Çakmakçı, Prof. Dr. Tarık Zafer Nursal, Dr. Mümtaz Özarar – via FL Comms.}

Preserving appearance and quality of life

Surgery is tailored to each patient. Breast‑conserving surgery is possible for the majority; when a mastectomy is necessary (for example, due to tumor or breast size), immediate reconstruction is performed in the same session, helping patients wake up with their body image preserved. “Our first aim is always to conserve the breast when it is oncologically safe. When we must remove it, we rebuild in the same operation,” said Prof. Çakmakçı.

Around‑the‑clock nurse navigation

Acıbadem’s dedicated breast‑care nurses follow each patient closely through diagnostics, treatment, and survivorship and are accessible 24/7 for urgent questions. This model underlines the hospital’s patient‑centered approach at every step.

Younger patients, real hope

While breast‑cancer incidence increases with age, Prof. Çakmakçı noted that young adults can also be affected. “We have many inspiring stories of patients diagnosed in their 20s or 30s who, after modern treatment, are healthy, start families, and lead full lives. Those stories stay with us.”

Why “Ready for All Rounds” now? The evidence behind the message

• Most common cancer worldwide: Female breast cancer is the most commonly diagnosed cancer, with an estimated 2.3 million new cases in 2020, and remains the leading cancer diagnosed in women.
• Early detection matters: Mortality decreases when breast cancer is detected and treated early; WHO highlights early diagnosis and mammography screening (typically in women 50–69) as the two complementary pillars of early detection programs.
• FL PR and Communications +90533 020 25 54 early; WHO highlights early diagnosis and mammography screening (typically in women 50–69) as the two complementary pillars of early detection programs
• Screening guidance: The U.S. Preventive Services Task Force (2024) recommends biennial mammography for women aged 40–74 at average risk (Grade B), underscoring the value of screening in lowering mortality. Screening decisions should always be personalized in consultation with a clinician.
• Outcomes when found early: In the U.S., the 5‑year relative survival for localized breast cancer exceeds 99%, illustrating how earlier detection can change prognosis.

If you are eligible for screening, speak with your clinician and book a mammogram. If you notice a new breast lump, skin change, or nipple discharge, seek medical evaluation promptly. For appointments and information about Acıbadem’s Breast Cancer Clinic, please contact us via the QR codes on hospital posters or through our patient services team.

Usage guidance:

• https://www.iarc.who.int/news-events/current-and-future-burden-of-breast-cancer-global-statistics-for-2020-and-2040
• https://www.who.int/news-room/fact-sheets/detail/breast-cancer
• https://www.uspreventiveservicestaskforce.org/uspstf/document/ClinicalSummaryFinal/breast-cancer-screening
• https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html

About Acıbadem’s Breast Cancer Clinic

The Acıbadem Breast Cancer Clinic in Istanbul provides end‑to‑end care — from same‑day diagnostic workups to individualized treatment and survivorship support — coordinated by a multidisciplinary team of breast surgeons, medical oncologists, radiologists, radiation oncologists, pathologists, plastic and reconstructive surgeons, and nuclear medicine physicians. With adjacent imaging and biopsy facilities on the same corridor and 24/7 nurse navigation, Acıbadem delivers timely, precise, and compassionate breast‑cancer care.

Media Contact:
FL PR and Communications
+90533 020 25 54

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/087fa5db-c01c-4dfd-aa30-4428051f84f4

https://www.globenewswire.com/NewsRoom/AttachmentNg/bd1fa474-6031-410d-9b43-d5f7388e8a9b

https://www.globenewswire.com/NewsRoom/AttachmentNg/11622abd-b071-4319-b225-3bb11f0c99d1

https://www.globenewswire.com/NewsRoom/AttachmentNg/b714c2d9-8611-4063-8351-11604fa2588e

Acıbadem Hospitals Launch “Ready for All Rounds” In‑Hospital Campaign for Breast Cancer Awareness Month




Acıbadem Hospitals Launch “Ready for All Rounds” In‑Hospital Campaign for Breast Cancer Awareness Month

Following last year’s heavy‑bag installation, this year’s activation features pink boxing gloves, a powerful reminder that early detection and multidisciplinary care help patients go the distance.

ISTANBUL, Sept. 25, 2025 (GLOBE NEWSWIRE) — Breast Cancer Awareness Month, observed every October worldwide, is a global health campaign recognised by the World Health Organization and leading cancer societies. Symbolised by the pink ribbon, the month is dedicated to raising awareness, promoting early detection, and supporting those affected by breast cancer through educational events, public screenings, community campaigns and fundraising initiatives.

Acıbadem Hospitals today announced its in‑hospital Breast Cancer Awareness Month campaign, “Ready for All Rounds,” an activation designed to meet patients and visitors where they are inside the hospital with clear calls to action for regular check‑ups and early diagnosis. Building on last year’s heavy punching‑bag installation, this year’s visual focus is pink boxing gloves arranged in the shape of the breast‑cancer ribbon, deployed across clinical corridors, radiology waiting areas, nurse stations, and digital hospital screens. The poster headline “WE ARE READY FOR ALL ROUNDS” with the educational line “Protect yourself with regular check‑ups, and stay strong against breast cancer with early diagnosis” anchors the creative.

“Breast cancer is one of more than 200 tumor types, yet it carries particular weight as the most common cancer worldwide. Each year, around 2.3 million people — predominantly women — receive this diagnosis,” said Professor Metin Çakmakçı, MD, breast‑cancer specialist at Acıbadem. “What changes the story is early detection and a coordinated, expert team.” (Global incidence reference: IARC.)

A campaign built around action inside the hospital

The in‑hospital program ensures that awareness immediately converts into action. Educational posters and screens guide visitors to on‑site breast imaging; staff remind eligible visitors about screening while clinical teams offer same‑day evaluations where appropriate. The creative theme of boxing gloves invites everyone to “step into the ring” for their health while reinforcing a simple message: book the check‑up now.

From first exam to definitive therapy — a comprehensive pathway under one roof

At the Acıbadem Breast Cancer Clinic, patients receive a detailed physical examination followed by appropriate radiologic evaluation (ultrasound, mammography, and/or MRI). When an abnormality such as a lump, mass, or suspicious calcification is detected, a needle biopsy is performed the same day; pathology results are typically ready within 2–3 days to confirm diagnosis and guide treatment. Treatment plans are individualized and may combine surgery, systemic drug therapy (chemotherapy, immunotherapy, targeted therapy, hormone therapy), and radiotherapy using advanced linear accelerators.

“Every physician who touches breast‑cancer care at Acıbadem — from radiology to surgical oncology, medical oncology, radiation oncology, pathology, plastic and reconstructive surgery, and nuclear medicine, literally works on the same corridor,” Prof. Çakmakçı added. “That proximity accelerates decisions, reduces patient anxiety, and improves outcomes, because our team can confer face‑to‑face in minutes rather than days.”

^{Photo: ACIBADEM INTERNATIONAL (from left to right) Prof. Dr. Bülent Saçak, Prof. Dr. Özge Gümüşay, Assoc. Prof. Özden Buturak, Prof. Dr. Metin Çakmakçı, Prof. Dr. Tarık Zafer Nursal, Dr. Mümtaz Özarar – via FL Comms.}

Preserving appearance and quality of life

Surgery is tailored to each patient. Breast‑conserving surgery is possible for the majority; when a mastectomy is necessary (for example, due to tumor or breast size), immediate reconstruction is performed in the same session, helping patients wake up with their body image preserved. “Our first aim is always to conserve the breast when it is oncologically safe. When we must remove it, we rebuild in the same operation,” said Prof. Çakmakçı.

Around‑the‑clock nurse navigation

Acıbadem’s dedicated breast‑care nurses follow each patient closely through diagnostics, treatment, and survivorship and are accessible 24/7 for urgent questions. This model underlines the hospital’s patient‑centered approach at every step.

Younger patients, real hope

While breast‑cancer incidence increases with age, Prof. Çakmakçı noted that young adults can also be affected. “We have many inspiring stories of patients diagnosed in their 20s or 30s who, after modern treatment, are healthy, start families, and lead full lives. Those stories stay with us.”

Why “Ready for All Rounds” now? The evidence behind the message

• Most common cancer worldwide: Female breast cancer is the most commonly diagnosed cancer, with an estimated 2.3 million new cases in 2020, and remains the leading cancer diagnosed in women.
• Early detection matters: Mortality decreases when breast cancer is detected and treated early; WHO highlights early diagnosis and mammography screening (typically in women 50–69) as the two complementary pillars of early detection programs.
• FL PR and Communications +90533 020 25 54 early; WHO highlights early diagnosis and mammography screening (typically in women 50–69) as the two complementary pillars of early detection programs
• Screening guidance: The U.S. Preventive Services Task Force (2024) recommends biennial mammography for women aged 40–74 at average risk (Grade B), underscoring the value of screening in lowering mortality. Screening decisions should always be personalized in consultation with a clinician.
• Outcomes when found early: In the U.S., the 5‑year relative survival for localized breast cancer exceeds 99%, illustrating how earlier detection can change prognosis.

If you are eligible for screening, speak with your clinician and book a mammogram. If you notice a new breast lump, skin change, or nipple discharge, seek medical evaluation promptly. For appointments and information about Acıbadem’s Breast Cancer Clinic, please contact us via the QR codes on hospital posters or through our patient services team.

Usage guidance:

• https://www.iarc.who.int/news-events/current-and-future-burden-of-breast-cancer-global-statistics-for-2020-and-2040
• https://www.who.int/news-room/fact-sheets/detail/breast-cancer
• https://www.uspreventiveservicestaskforce.org/uspstf/document/ClinicalSummaryFinal/breast-cancer-screening
• https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html

About Acıbadem’s Breast Cancer Clinic

The Acıbadem Breast Cancer Clinic in Istanbul provides end‑to‑end care — from same‑day diagnostic workups to individualized treatment and survivorship support — coordinated by a multidisciplinary team of breast surgeons, medical oncologists, radiologists, radiation oncologists, pathologists, plastic and reconstructive surgeons, and nuclear medicine physicians. With adjacent imaging and biopsy facilities on the same corridor and 24/7 nurse navigation, Acıbadem delivers timely, precise, and compassionate breast‑cancer care.

Media Contact:
FL PR and Communications
+90533 020 25 54

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/087fa5db-c01c-4dfd-aa30-4428051f84f4

https://www.globenewswire.com/NewsRoom/AttachmentNg/bd1fa474-6031-410d-9b43-d5f7388e8a9b

https://www.globenewswire.com/NewsRoom/AttachmentNg/11622abd-b071-4319-b225-3bb11f0c99d1

https://www.globenewswire.com/NewsRoom/AttachmentNg/b714c2d9-8611-4063-8351-11604fa2588e

OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025




OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025

OSE Immunotherapeutics Reports its Cash Position
as of June 30, 2025

Nantes, France, September 25, 2025, 6 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) reports its cash position as of June 30, 2025. Due to the Company’s Annual General Meeting being rescheduled to September 30, 2025, and to allow shareholders to first approve 2024 financial statements, the full 2025 half-year interim financial results will be published on October 15, 2025.

Update on AbbVie Partnership related to ABBV-230

The Company initially expected the initiation of Phase 1 trial of ABBV-230 and the related milestone payment in late 2025. Based on current discussions with its partner, the Company now anticipates a delay in the development timeline.

As the Company has no control over the start of this trial, and in line with the principle of prudence, it has chosen to exclude from its current cash projections the related milestone payment from AbbVie.

Cash Position as of June 30, 2025

As of June 30, 2025, OSE Immunotherapeutics’ cash position totalled €41.6 million, compared to €64.2 million as of December 31, 2024.

The cash position includes cash, cash equivalents and fixed-term deposits classified as current and non-current financial assets. As of June 30, 2025, cash and cash equivalents amounted to €25.4 million while fixed-term deposits classified as current and non-current current-financial assets amounted to €16.2 million.

Based on current assumptions and available financial resources, the Company considers that its operations are funded until the beginning of Q4 2026. This cash runway includes a possible exercise of remaining warrants issued to the benefit of Vester Finance¹ but no longer factors in any upcoming milestone from current partnerships. Should one of the anticipated milestones be received in 2026, the cash runway would be extended to at least Q1 2027, as previously communicated.

To extend its runway beyond 2026, the Company continues to evaluate several complementary options, including a potential new strategic partnership involving one of its proprietary assets, equity financing and restructuring of its existing debt in addition to potential milestone payments from current partnerships.

2025 Half-Year Interim Financial Results

Due to the rescheduling of the Company’s Annual General Meeting to September 30, 2025, and to allow shareholders to first approve the 2024 financial statements, the full 2025 half-year interim financial results will be published on October 15, 2025.

ABOUT OSE IMMUNOTHERAPEUTICS  
OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company’s website: www.ose-immuno.com. Click and follow us on LinkedIn.

Follow us on Linkedln.

Contacts

Forward-looking statements
This press release contains express or implied information and statements that might be deemed forward-looking in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.

These forward-looking statements can often be identified by the use of the conditional tense and by verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations as well as other similar terms. Although the management of OSE Immunotherapeutics believes that the forward-looking statements and information are reasonable, OSE Immunotherapeutics shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics within the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read alongside OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on OSE Immunotherapeutics’ website. Other than as required by applicable laws, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.

1 Retained assumption is a full exercise of the remaining 880,000 warrants by Vester Finance at an estimated price of €6.00 per share.

Attachment

• 250925_EN_2025 June 30 Cash Position_vF

OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025




OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025

OSE Immunotherapeutics Reports its Cash Position
as of June 30, 2025

Nantes, France, September 25, 2025, 6 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) reports its cash position as of June 30, 2025. Due to the Company’s Annual General Meeting being rescheduled to September 30, 2025, and to allow shareholders to first approve 2024 financial statements, the full 2025 half-year interim financial results will be published on October 15, 2025.

Update on AbbVie Partnership related to ABBV-230

The Company initially expected the initiation of Phase 1 trial of ABBV-230 and the related milestone payment in late 2025. Based on current discussions with its partner, the Company now anticipates a delay in the development timeline.

As the Company has no control over the start of this trial, and in line with the principle of prudence, it has chosen to exclude from its current cash projections the related milestone payment from AbbVie.

Cash Position as of June 30, 2025

As of June 30, 2025, OSE Immunotherapeutics’ cash position totalled €41.6 million, compared to €64.2 million as of December 31, 2024.

The cash position includes cash, cash equivalents and fixed-term deposits classified as current and non-current financial assets. As of June 30, 2025, cash and cash equivalents amounted to €25.4 million while fixed-term deposits classified as current and non-current current-financial assets amounted to €16.2 million.

Based on current assumptions and available financial resources, the Company considers that its operations are funded until the beginning of Q4 2026. This cash runway includes a possible exercise of remaining warrants issued to the benefit of Vester Finance¹ but no longer factors in any upcoming milestone from current partnerships. Should one of the anticipated milestones be received in 2026, the cash runway would be extended to at least Q1 2027, as previously communicated.

To extend its runway beyond 2026, the Company continues to evaluate several complementary options, including a potential new strategic partnership involving one of its proprietary assets, equity financing and restructuring of its existing debt in addition to potential milestone payments from current partnerships.

2025 Half-Year Interim Financial Results

Due to the rescheduling of the Company’s Annual General Meeting to September 30, 2025, and to allow shareholders to first approve the 2024 financial statements, the full 2025 half-year interim financial results will be published on October 15, 2025.

ABOUT OSE IMMUNOTHERAPEUTICS  
OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company’s website: www.ose-immuno.com. Click and follow us on LinkedIn.

Follow us on Linkedln.

Contacts

Forward-looking statements
This press release contains express or implied information and statements that might be deemed forward-looking in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.

These forward-looking statements can often be identified by the use of the conditional tense and by verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations as well as other similar terms. Although the management of OSE Immunotherapeutics believes that the forward-looking statements and information are reasonable, OSE Immunotherapeutics shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics within the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read alongside OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on OSE Immunotherapeutics’ website. Other than as required by applicable laws, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.

1 Retained assumption is a full exercise of the remaining 880,000 warrants by Vester Finance at an estimated price of €6.00 per share.

Attachment

• 250925_EN_2025 June 30 Cash Position_vF